Ronald H. W. M. Derksen

Ronald H. W. M. Derksen publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Ronald H. W. M. Derksen sits on this spectrum.

Ronald H. W. M. Derksen D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Ronald H. W. M. Derksen sits on this spectrum.

Overview

Best Publications

• International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

  S. Miyakis;M. D. Lockshin;T. Atsumi;D. W. Branch

  8617
  Citations

• Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients

  Ricard Cervera;Jean Charles Piette;Josep Font;Munther A. Khamashta

  2492
  Citations

• Treat-to-target in systemic lupus erythematosus: recommendations from an international task force

  Ronald van Vollenhoven;Marta Mosca;George Bertsias;David Isenberg

  846
  Citations

• Anti-inflammatory and immunosuppressive drugs and reproduction.

  Monika Østensen;Munther Khamashta;Michael Lockshin;Ann Parke

  683
  Citations

• IgG antibodies that recognize epitope Gly40-Arg43 in domain I of β2–glycoprotein I cause LAC, and their presence correlates strongly with thrombosis

  Bas de Laat;Ronald H. W. M. Derksen;Rolf T. Urbanus;Philip G. de Groot

  471
  Citations

• Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure.

  Barend Bouma;Philip G. de Groot;Jean M.H. van den Elsen;Raimond B.G. Ravelli

  449
  Citations

• A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)

  Ronald van Vollenhoven;Alexandre Voskuyl;George Bertsias;Cynthia Aranow

  382
  Citations

• Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies.

  Henk J. Out;Carole D. Kooijman;Hein W. Bruinse;Ronald H.W.M. Derksen

  366
  Citations

• Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies.

  Daniëlle A Horbach;Erica V Oort;Richard C J M Donders;Ronald H W M Derksen

  365
  Citations

• β2-Glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome

  Çetin Ağar;Çetin Ağar;Gwendolyn M. A. van Os;Gwendolyn M. A. van Os;Matthias Mörgelin;Richard R. Sprenger

  325
  Citations

• Dimers of β2-Glycoprotein I Increase Platelet Deposition to Collagen via Interaction with Phospholipids and the Apolipoprotein E Receptor 2′

  Bianca C H Lutters;Ronald H W M Derksen;Winnie L Tekelenburg;Peter J Lenting

  319
  Citations

• β2-glycoprotein I–dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome

  H. Bas de Laat;Ronald H.W.M. Derksen;Rolf T. Urbanus;Mark Roest

  303
  Citations

• Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients

  A J Duits;H Bootsma;R H Derksen;P E Spronk

  296
  Citations

• Pathogenic anti-β2-glycoprotein I antibodies recognize domain I of β2-glycoprotein I only after a conformational change

  Bas de Laat;Ronald H. W. M. Derksen;Menno van Lummel;Maarten T. T. Pennings

  291
  Citations

• Management of the obstetric antiphospholipid syndrome.

  Ronald H. W. M. Derksen;Munther A. Khamashta;D. Ware Branch

  223
  Citations

• A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies.

  Henk J. Out;Hein W. Bruinse;Godelieve C.M.L. Christiaens;Marja van Vliet

  211
  Citations

• Chorea in systemic lupus erythematosus and "lupus-like" disease: association with antiphospholipid antibodies.

  R.A. Asherson;R.H.W.M. Derksen;E.N. Harris;B.N. Bouma

  211
  Citations

• Fcγ receptor polymorphisms in systemic lupus erythematosus: Association with disease and in vivo clearance of immune complexes

  Hilde M. Dijstelbloem;Marc Bijl;Rob Fijnheer;Ronald H. M. Scheepers

  182
  Citations

• Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus

  Peter E. Westerweel;Remco K. M. A. C. Luyten;Hein A. Koomans;Ronald H. W. M. Derksen

  178
  Citations

• Pathophysiology of the antiphospholipid syndrome

  P. G. De Groot;R. H. W. M. Derksen

  171
  Citations

• Correlation between antiphospholipid antibodies that recognize domain I of β2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5

  Bas de Laat;Xiao-Xuan Wu;Menno van Lummel;Ronald H. W. M. Derksen

  163
  Citations

• Haematopoietic and endothelial progenitor cells are deficient in quiescent Systemic Lupus Erythematosus

  Peter E Westerweel;Remco K M A C Luijten;Imo E Hoefer;Hein A Koomans

  162
  Citations

• Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome.

  Zurina Romay-Penabad;Renan Aguilar-Valenzuela;Rolf T. Urbanus;Ronald H. W. M. Derksen

  140
  Citations

• Dimers of beta 2-glycoprotein I mimic the in vitro effects of beta 2-glycoprotein I-anti-beta 2-glycoprotein I antibody complexes.

  Bianca C.H. Lutters;Joost C.M. Meijers;Ronald H. W.M. Derksen;Jef Arnout

  119
  Citations